The approval will expand lupin's range of suprax dosage forms available to treat the approved indications in appropriate patients suprax is currently available?

It sounds like you’re referring to a regulatory approval that expands Lupin’s Suprax dosage forms for approved indications. If you’d like, I can help with one of the following:

- Rewrite for a press release or article
- A concise summary of what this expansion means for patients and clinicians
- General information about Suprax (cefixime): what dosage forms exist (typical forms are oral suspension and tablets) and common indications
- Look up or draft details if you share the market (e.g., US, India) and the date or a link to the announcement

A quick note on Suprax: it’s cefixime, a third-generation cephalosporin antibiotic. It’s commonly available in oral forms (tablets and oral suspension) and is used to treat various infections such as certain respiratory infections, otitis media, sinusitis, uncomplicated urinary tract infections, and, in some indications, certain sexually transmitted infections. Exact approved indications and dosage forms can vary by country and labeling.

Tell me which option you’d prefer, or provide more context (country, date, link), and I’ll tailor the response.